NASDAQ$TOI
Oncology Institute Inc/The · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported strong growth with increased gross profit and reduced SG&A expenses.
The Oncology Institute reported a 26% increase in consolidated revenue, reaching $82 million for Q3 2023. Gross profit increased by 23% to $16 million, while the company experienced a net loss of $17.4 million. The company reaffirmed its full year 2023 guidance.
- Consolidated revenue increased by 26% to $82 million compared to the prior year quarter.
- Gross profit increased by 23% to $16 million compared to the prior year quarter.
- Net loss was $17.4 million, compared to a net loss of $2.7 million for the prior year quarter.
- The company opened its 70th clinic and added 5 physicians, bringing the total provider count to 112.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$82M
Revenue by segment
Oncology Institute · $82M total across 3 segments · Q3 2023
- Patient Services$53.6M+20.2%65.4%
- Dispensary$26.8M+42.2%32.7%
- Clinical Trials & Other$1.61M—2.0%
Forward guidance
The Oncology Institute reaffirmed its fiscal year 2023 guidance.
Tailwinds
- Revenue between $290 to $320 million, representing approximately 15% to 27% growth over 2022 revenue
- Gross Profit between $60 to $70 million
- Adjusted EBITDA between $(25) to $(28) million
- Value-based lives between 1.75 million to 2.0 million lives
- Expects interest expense in the range of $4 million to $5 million
Headwinds
- Uncertainties regarding taxes
- Share-based compensation
- Goodwill impairment charges
- Change in fair value of liabilities
- Unrealized (gains) losses on investments
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro